Keywords: b-ms, licenses, novartis, hiv, protease, inhibitors, bristol-myers

B-MS Licenses Novartis HIV Protease Inhibitors

Article | 09 June 1997

Print This

Bristol-Myers Squibb has licensed two HIV protease inhibitors fromNovartis, in a bid to flesh out its portfolio of antiretrovirals. The ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in